Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics Cancer Therapeutics

2023-10-16

免疫疗法抗体药物偶联物

Collaboration successfully identified antibodies with therapeutic potential as checkpoint inhibitors in oncology Two antibodies showing high specificity for PD-1 are now being progressed to preclinical development Project leveraged Antiverse’s AI-driven Antibody Discovery Platform and GlobalBio’s ALTHEA semisynthetic libraries CARDIFF, Wales & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engineer improved and more developable therapeutic antibodies, today announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy. The initial collaboration successfully resulted in the generation of a panel of anti-PD-1 antibodies anti-PD-1 antibodies anti-PD-1 antibodies anti-PD-1 antibodies anti-PD-1 antibodies with diverse binding and functional pro with two candidates from this panel now entering preclinical development. This press release features multimedia. View the full release here: The collaboration leveraged Antiverse’s proprietary AI-driven Antibody Discovery platform, which uses state-of-the-art machine learning techniques and advanced cell line engineering to develop antibodies for difficult drug targets, alongside GlobalBio’s ALTHEA semisynthetic libraries for the discovery and optimization of antibody-based therapeutics. Through rounds of selection using recombinant human PD-1 as a selector, more than 300 clones were tested for their ability to bind human PD-1 and PD-1 orthologs of mouse, dog and cynomolgus. Among these clones, over a hundred were demonstrated to be positive binders to PD-1, with several dozen showing high specificity for human PD-1 and/or cross-reactivity with mouse, dog and cynomolgus orthologs. The best-performing clones were converted to antibody isotypes to minimize toxicity. Several antibodies exhibited the ability to block PD-1:PD-L1 and PD-1:PD-L2 interactions in ELISA assays and Jurkat cells, and some promoted expression of Interferon-gamma in a mixed lymphocyte reaction co-culture assay. Antibodies D6, highly specific for human PD-1, and D13, cross-reactive with dog PD-1 and related variants, are now progressing to preclinical development in an extension of the collaboration. Ben Holland, Co-founder and CTO of Antiverse, said: “This Agreement is further validation of our AI-driven drug discovery platform, successfully generating a panel of anti-PD-1 antibodies anti-PD-1 antibodies anti-PD-1 antibodies anti-PD-1 antibodies anti-PD-1 antibodies, with at least two potential candidates entering preclinical development. Through these types of innovative collaborations, Antiverse plays a vital role in accelerating the identification and development of novel antibody therapeutics for cancer, reducing drug discovery timelines and costs. We aim to continue to ‘open up’ the druggable antibody space.” Dr Juan Carlos Almagro, Founder and CEO at GlobalBio, Inc., added: “Antiverse’s antibody discovery platform complements our libraries and antibody engineering capabilities well. Through this collaboration, we have highlighted an exciting new avenue for us to bring new antibody-based checkpoint inhibitors into the immuno-oncology market for the treatment of cancers in both humans and animals.” For more information about Antiverse’s antibody drug discovery platform, please visit: View source version on businesswire.com: Contacts Francesca Wallace Zyme Communications Tel: +44(0)7506424870 Email: francesca.wallace@zymecommunications.com Source: Antiverse Ltd View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构